BioWorld-International-2008-01-09
Addex, Merck Ink $702M Deal for Schizophrenia Compound
Addex, Merck Ink $702M Deal for Schizophrenia Compound
Merck & Co. Inc. demonstrated its liking for Addex Pharmaceuticals AG's approach to modulating glutamate receptors by entering a second deal with the Swiss firm in consecutive months. (BioWorld International)

